^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IBI-334
i
Other names: IBI-334, IBI334
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innovent Biologics
Drug class:
EGFR inhibitor, B7-H3 inhibitor
Related drugs:
29d
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. (clinicaltrials.gov)
P1/2, N=28, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=128 --> 28 | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Oct 2025 --> Mar 2025
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
IBI-334
2years
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=128, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Phase classification: P1 --> P1/2
Phase classification
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
IBI-334
over2years
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=128, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
IBI-334
almost3years
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=128, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
New P1 trial • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
IBI-334
Share via
